4-(3-pyridin-2-yl[1,2,4]oxadiazol-5-yl)piperidine-1-carboxylic acid tert-butyl ester | 1001467-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3-pyridin-2-yl[1,2,4]oxadiazol-5-yl)piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate；tert-butyl 4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate
• CAS: 1001467-22-6
• 化学式: C₁₇H₂₂N₄O₃
• 分子量: 330.387
• InChiKey: UJCKXZSXHUXTMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(3-pyridin-2-yl[1,2,4]oxadiazol-5-yl)piperidine-1-carboxylic acid tert-butyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-(5-piperidin-4-yl[1,2,4]oxadiazol-3-yl)pyridine hydrochloride
  参考文献：
  名称：

  Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors

  摘要：

  Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure-property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration.

  DOI：

  10.1021/jm200825u
• 作为产物：
  描述：

  2-吡啶基脒肟 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 生成 4-(3-pyridin-2-yl[1,2,4]oxadiazol-5-yl)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors

  摘要：

  Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure-property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration.

  DOI：

  10.1021/jm200825u

文献信息

• COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF
  申请人：Deprez Benôit

  公开号：US20110136823A1

  公开（公告）日：2011-06-09

  The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy.

  本发明涉及具有增强抗生素活性的化合物，这些抗生素通过EthA酶途径可激活，用于制备预防和/或治疗如结核病和麻风病等分枝杆菌感染的药物；涉及包含这些化合物与通过EthA途径可激活的抗生素组合的药物组合物；涉及具有增强通过EthA酶途径可激活抗生素活性的化合物；涉及包含这些化合物的药物组合物；以及涉及它们作为药物，特别是用于预防和/或治疗如结核病和麻风病等分枝杆菌感染的药物的使用。
• Discovery of a Highly Potent, Selective, and Bioavailable Soluble Epoxide Hydrolase Inhibitor with Excellent Ex Vivo Target Engagement
  作者：Hong C. Shen、Fa-Xiang Ding、Siyi Wang、Qiaolin Deng、Xiaoping Zhang、Yuli Chen、Gaochao Zhou、Suoyu Xu、Hsuan-shen Chen、Xinchun Tong、Vincent Tong、Kaushik Mitra、Sanjeev Kumar、Christine Tsai、Andra S. Stevenson、Lee-Yuh Pai、Magdalena Alonso-Galicia、Xiaoli Chen、Stephen M. Soisson、Sophie Roy、Bei Zhang、James R. Tata、Joel P. Berger、Steven L. Colletti

  DOI：10.1021/jm900725r

  日期：2009.8.27

  piperidine-derived trisubstituted ureas are reported as highly potent and selective inhibitors for sEH. The SAR outlines approaches to improve activity against sEH and reduce ion channel and CYP liability. With minimal off-target activity and a good PK profile, the benchmark 2d exhibited remarkable in vitro and ex vivo target engagement. The eutomer entA-2d also elicited vasodilation effect in rat mesenteric

  据报道，4-取代的哌啶衍生的三取代脲是sEH的高效抑制剂。SAR概述了提高抗sEH活性并减少离子通道和CYP危害的方法。具有最小的脱靶活性和良好的PK分布，基准2d表现出了卓越的体外和离体靶标参与。Eutomer ent A - 2d也引起大鼠肠系膜动脉的血管舒张作用。
• US8338599B2
  申请人：——

  公开号：US8338599B2

  公开（公告）日：2012-12-25